“Adalimumab Efficacy in Hidradenitis Suppurativa Patients is Sustained at Least Three Years with Weekly Dosing: Results from a Phase 3 Open-Label Extension Study (PIONEER)”, J of Skin, vol. 1, no. 3.1, p. s128, Oct. 2017, doi: 10.25251/skin.1.supp.127.